Small vessel vasculitis of the lung
暂无分享,去创建一个
[1] C. Kallenberg,et al. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. , 2010, Arthritis and rheumatism.
[2] F. Woude. Taking anti‐neutrophil cytoplasmic antibody (ANCA) testing beyond the limits , 2002 .
[3] M. Heller,et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. , 2002, Rheumatology.
[4] L. Guillevin,et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. , 2002, Rheumatology.
[5] K. Brown,et al. Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa, and Takayasu arteritis. , 2002, Critical care clinics.
[6] J. Katz,et al. Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? , 2002, Archives of internal medicine.
[7] K. De Groot,et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. , 2002, Arthritis and rheumatism.
[8] M. Haubitz,et al. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. , 2002, Clinical nephrology.
[9] D. Schroeder,et al. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. , 2002, Clinical immunology.
[10] W. Koldingsnes,et al. Predictors of survival and organ damage in Wegener's granulomatosis. , 2002, Rheumatology.
[11] G. Hoffman,et al. Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. , 2002, The Journal of rheumatology.
[12] M. Hogan,et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. , 2001, Arthritis and rheumatism.
[13] D. Adu,et al. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] M. Kimura,et al. Generalized Wegener's granulomatosis responding to sulfamethoxazole-trimethoprim monotherapy. , 2001, Internal medicine.
[15] G A Colditz,et al. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. , 2001, The Journal of rheumatology.
[16] R. Solans,et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. , 2001, Rheumatology.
[17] C. Pusey,et al. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[18] J. Stone,et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. , 2001, Arthritis and rheumatism.
[19] L. Bostad,et al. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] L. Guillevin,et al. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. , 2001, Rheumatology.
[21] L. Guillevin,et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. , 2001, Arthritis and rheumatism.
[22] C. Kallenberg,et al. Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis , 2001, Current opinion in nephrology and hypertension.
[23] P. Lamprecht,et al. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. , 2001, Rheumatology.
[24] M. André,et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. , 2001, Rheumatology.
[25] M. Madaio,et al. The diagnosis of glomerular diseases: acute glomerulonephritis and the nephrotic syndrome. , 2001, Archives of internal medicine.
[26] D. Jayne. Update on the European Vasculitis Study Group trials , 2001, Current opinion in rheumatology.
[27] J Stebbing,et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. , 2000, Arthritis care and research : the official journal of the Arthritis Health Professions Association.
[28] C. Langford,et al. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. , 2000, Arthritis and rheumatism.
[29] D. Adu,et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. , 2000, QJM : monthly journal of the Association of Physicians.
[30] D. Jayne. Evidence-based treatment of systemic vasculitis. , 2000, Rheumatology.
[31] C. Kallenberg,et al. New treatments of ANCA-associated vasculitis. , 2000, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[32] Søren Freiesleben Sørensen,et al. A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature , 2000, Annals of the rheumatic diseases.
[33] M. Heller,et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. , 2000, Arthritis and rheumatism.
[34] L. Vatten,et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[35] M. Haas,et al. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[36] D. Scott,et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. , 2000, Arthritis and rheumatism.
[37] K. Andrassy,et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. , 1999, Journal of the American Society of Nephrology : JASN.
[38] E. Mirapeix,et al. Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[39] J. Stone,et al. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. , 1999, The Journal of rheumatology.
[40] Y. Shoenfeld,et al. Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. , 1999, Southern medical journal.
[41] R J Falk,et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) , 1999, American journal of clinical pathology.
[42] J. Amouroux,et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. , 1999, Arthritis and rheumatism.
[43] T. Pincus,et al. Limitations of the 1990 American College of Rheumatology Classification Criteria in the Diagnosis of Vasculitis , 1998, Annals of Internal Medicine.
[44] M. Heller,et al. Pulmonary Wegener's granulomatosis: correlation between high-resolution CT findings and clinical scoring of disease activity. , 1998, Chest.
[45] L. Guillevin,et al. Polyarteritis nodosa, microscopic polyangiitis and Churg–Strauss syndrome , 1998, Lupus.
[46] K. De Groot,et al. Induction of remission in Wegener's granulomatosis with low dose methotrexate. , 1998, The Journal of rheumatology.
[47] P Lesavre,et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. , 1998, Kidney international.
[48] K. Dalhoff,et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. , 1997, The European respiratory journal.
[49] R. Gherardi,et al. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: clinical aspects, neurologic manifestations, and treatment. , 1997, Neurologic clinics.
[50] M. Zamora,et al. Diffuse Alveolar Hemorrhage and Systemic Lupus Erythematosus: Clinical Presentation, Histology, Survival, and Outcome , 1997, Medicine.
[51] Bolton Wk. RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS , 1996 .
[52] G. Hunder,et al. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. , 1996, The American journal of medicine.
[53] C. Kallenberg,et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis , 1996 .
[54] E. Böttinger,et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. , 1996, Archives of internal medicine.
[55] W. Gross,et al. Antineutrophil cytoplasmic autoantibody testing in vasculitides. , 1995, Rheumatic diseases clinics of North America.
[56] O. Lortholary,et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. , 1995, Arthritis and rheumatism.
[57] R. Saxena,et al. Circulating autoantibodies as serological markers in the differential diagnosis of pulmonary renal syndrome , 1995, Journal of internal medicine.
[58] R. Falk,et al. Clinical and pathological classification of ANCA‐associated vasculitis: what are the controversies? , 1995, Clinical and experimental immunology.
[59] Guy Hoffman,et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. , 1995, Arthritis and rheumatism.
[60] R. Porter. Nomenclature of Systemic Vasculitides: Proposal of an International Consensus Conference , 1995 .
[61] L. Noel,et al. Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. , 1995, Clinical and experimental rheumatology.
[62] A. Dash,et al. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[63] U. Specks,et al. Anti-neutrophil cytoplasmic antibodies. , 1994, Mayo Clinic proceedings.
[64] L. Calabrese,et al. Neurologic manifestations of systemic vasculitides. , 1994, Seminars in neurology.
[65] R. Moots,et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.
[66] R. Falk,et al. The pathology of vasculitis involving the kidney. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[67] L. Noel,et al. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome--62 patients. , 1994, The Journal of rheumatology.
[68] R J Falk,et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.
[69] D. Adu,et al. Relapses in patients with a systemic vasculitis. , 1993, The Quarterly journal of medicine.
[70] A. D'apice,et al. Wegener's granulomatosis: clinical features and prognosis in 37 patients. , 1993, Australian and New Zealand journal of medicine.
[71] L. Revert,et al. Antimyeloperoxidase autoantibody-associated necrotizing alveolar capillaritis. , 1992, The American review of respiratory disease.
[72] Guy Hoffman,et al. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. , 1992, Arthritis and rheumatism.
[73] J. Grünfeld,et al. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis , 1992, Clinical and experimental immunology.
[74] A. Douglas,et al. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. , 1992, The Quarterly journal of medicine.
[75] Guy Hoffman,et al. Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.
[76] C. Pusey,et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. , 1991, Kidney international.
[77] R. Goldschmeding,et al. Antimyeloperoxidase antibodies in the Churg-Strauss syndrome , 1991, Thorax.
[78] T. Carey,et al. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. , 1990, Annals of internal medicine.
[79] Guy Hoffman,et al. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. , 1990, The American journal of medicine.
[80] Guy Hoffman,et al. Interpretation of Head and Neck Biopsies in Wegener's Granulomatosis: A Pathologic Study of 126 Biopsies in 70 Patients , 1990, The American journal of surgical pathology.
[81] R. Loire,et al. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. , 1990, Chest.
[82] A. Stuck,et al. Risk of infectious complications in patients taking glucocorticosteroids. , 1989, Reviews of infectious diseases.
[83] C. Kallenberg,et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. , 1989, Archives of internal medicine.
[84] Bousser Mg,et al. Vasculitis of the central nervous system , 1989 .
[85] R. Swerlick,et al. Cutaneous vasculitis: its relationship to systemic disease. , 1989, The Medical clinics of North America.
[86] U. Specks,et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. , 1989, Annals of internal medicine.
[87] A. Fauci,et al. Response: The role of trimethoprim/sulfamethoxazole in the treatment of Wegener's granulomatosis , 1988 .
[88] R. Falk,et al. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. , 1988, The New England journal of medicine.
[89] D. Scott,et al. Polyarteritis and the kidney. , 1987, The Quarterly journal of medicine.
[90] J. Crissman,et al. Segmental necrotizing glomerulonephritis: diagnostic, prognostic, and therapeutic significance. , 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[91] C. Savage,et al. Microscopic polyarteritis: presentation, pathology and prognosis. , 1985, The Quarterly journal of medicine.
[92] G. Hughes,et al. Systemic Vasculitis with Asthma and Eosinophilia: A Clinical Approach to the Churg‐Strauss Syndrome , 1984, Medicine.
[93] A. Fauci,et al. Neurologic manifestations of systemic vasculitis. A retrospective and prospective study of the clinicopathologic features and responses to therapy in 25 patients. , 1981, American Journal of Medicine.
[94] Hans C van Houwelingen,et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. , 2002, Kidney international.
[95] F. J. van der Woude. Taking anti-neutrophil cytoplasmic antibody (ANCA) testing beyond the limits. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[96] J. P. Venetz,et al. [Microscopic polyangiitis]. , 2000, Annales de medecine interne.
[97] L. Guillevin,et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. , 1999, Medicine.
[98] D. Jayne. Pulmonary-Renal Syndrome , 1998 .
[99] G. Hoffman,et al. Antineutrophil cytoplasmic antibodies. , 1998, Arthritis and rheumatism.
[100] G. Hoffman,et al. Pulmonary vasculitis. , 1998, Clinics in chest medicine.
[101] M. Cotch,et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. , 1996, Arthritis and rheumatism.
[102] R. Falk,et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.
[103] W. K. Bolton. Rapidly progressive glomerulonephritis. , 1996, Seminars in nephrology.
[104] O. Lortholary,et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. , 1996, Medicine.
[105] M. Heller,et al. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. , 1996, QJM : monthly journal of the Association of Physicians.
[106] C. Kallenberg,et al. Association of Chronic Nasal Carriage of Staphylococcus aureus and Higher Relapse Rates in Wegener Granulomatosis , 1994, Annals of Internal Medicine.
[107] C. Hallahan,et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosis. , 1993, Advances in experimental medicine and biology.
[108] C. Pusey,et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[109] K. Brandt,et al. Infectious complications of cyclophosphamide treatment for vasculitis. , 1989, Arthritis and rheumatism.
[110] B. Haynes,et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. , 1983, Annals of internal medicine.